NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS

描述：(改编自《调查员摘要》) 建议的第一阶段研究是探索流感病毒的新方法 口服或口服微囊化抗原接种疫苗 鼻腔途径，以诱导保护性黏膜免疫反应。 小鼠将接种纯化的甲型H3N2流感病毒(乌多恩) 在溶液中游离或包裹在可生物降解的微球中，口服， 鼻腔途径，或系统途径。诱导物的水平和同种类型， 将在血清和分泌物中检测抗原特异性免疫球蛋白 从免疫的小鼠身上采集。将获得的数据进行关联 具有递送抗原的形式(在溶液中或 微球)和给药途径(全身、口服或 鼻腔)。这些研究预计将提供关于以下方面的信息 诱导具有保护作用的抗体的最有效途径 预防流感病毒感染。使用的潜在优势 生物相容性和生物可降解性微球作为抗原递送载体 包括：保护和控制释放相对较高数量的 抗原、佐剂作用和选择性刺激分泌或 全身免疫反应根据微球的大小而定。之后 微囊化流感病毒免疫原性的初步研究 小鼠在第一阶段研究中，这项研究将在#年继续进行第二阶段研究 另一个动物模型，松鼠猴子。这个型号更适合于 由于猴子之间的相似性，疫苗效力的评估 和人类免疫系统，因为可以获得一种 适合在猴子身上感染的流感病毒(乌多恩)。

DESCRIPTION: (Adapted from the Investigator's Abstract) The purpose of the proposed Phase I study is to explore a novel approach for influenza virus vaccination by using microencapsulated antigen administered by the oral or intranasal route in order to induce a protective mucosal immune response. Mice will be immunized with purified influenza virus type A H3N2 (Udorn) free in solution or encapsulated in biodegradable microspheres, by oral, intranasal, or systematic routes. The levels and isotype of the induced, antigen-specific immunoglobulins will be determined in sera and secretion collected from the immunized mice. The data obtained will be correlated with the form by which the antigen was delivered (free in the solution or in microspheres) and with the route of administration (systemic, oral, or intranasal). These studies are expected to provide information concerning the most effective route for induction of antibodies with a protective role against influenza virus infections. Potential advantages for using biocompatible and biodegradable microspheres as an antigen delivery vehicle include: protection and controlled release of relatively high amounts of antigen, an adjuvant effect, and selective stimulation of secretory or systemic immune response according to the size of microspheres. After establishing the immunogenicity of microencapsulated influenza virus in mice in Phase I research, the studies will be continued in Phase II in another animal model, squirrel monkeys. This model is more suitable for assessment of vaccine efficacy because of the similarities between monkey and human immune systems and because of the availability of a strain of influenza virus (Udorn) adapted to be infective in monkeys.